| Literature DB >> 29946560 |
Tomoaki Hama1, Keiko Oikawa1, Akiko Ushijima1, Norishige Morita1, Takashi Matsukage1, Yu-Ji Ikari2, Yoshinori Kobayashi1.
Abstract
BACKGROUND: Whether an individually determined appropriate level of cardiac rehabilitation (CR) has a favorable effect on the renal function still remains unclarified. The aim of this study was to confirm the effect of CR on the estimated glomerular filtration rate (eGFR) using cystatin C, which is known to be unaffected by physical exercise.Entities:
Keywords: Cardiac rehabilitation; Cardiovascular disease; Chronic kidney disease; Cystatin C; Estimated glomerular filtration rate; Exercise capacity
Year: 2018 PMID: 29946560 PMCID: PMC6016066 DOI: 10.1016/j.ijcha.2018.04.001
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Fig. 1Enrollment.
Baseline characteristics. Data are expressed as the mean ± standard deviation or number (%).
| Total ( | |
|---|---|
| Age (years) | 74 ± 9 |
| Sex (M/F) | 61/25 |
| BMI (kg/m2) | 22.3 ± 3 |
| Angina pectoris | 31 (36%) |
| Myocardial infarction | 22 (26%) |
| Silent myocardial ischemia | 15 (17%) |
| Non-ischemic heart failure | 18 (21%) |
| Post-cardiac surgery | 30 (35%) |
| Smoking | 50 (58%) |
| Hypertension | 54 (63%) |
| Diabetes mellitus | 33 (38%) |
| Dyslipidemia | 52 (60%) |
| Family history | 16 (19%) |
| ACE-I/ARB | 44 (51%) |
| Βeta-blocker | 58 (67%) |
| Diuretics | 63 (73%) |
| Calcium channel blocker | 25 (29%) |
| Inotropic agents | 0 (0%) |
| Triglyceride (casual) (mg/dl) | 132 ± 55 |
| LDL-Chol (mg/dl) | 95 ± 32 |
| HDL-Chol (mg/dl) | 52 ± 15 |
| Blood glucose (casual) (mg/dl) | 130 ± 41 |
| HbA1c (%) | 6.2 ± 0.8 |
| BNP (pg/ml) | 224 ± 303 |
| Hb (g/dl) | 12.3 ± 1.7 |
| Scr (mg/dl) | 1.2 ± 0.4 |
| eGFRcr (ml/min/1.73 m2) | 45.1 ± 12 |
| Scys (mg/l) | 1.5 ± 0.4 |
| eGFRcys (ml/min/1.73 m2) | 45.2 ± 11 |
| CRP (mg/dl) | 0.32 ± 0.55 |
| G3a | 51 (59%) |
| G3b | 24 (28%) |
| G4 | 11 (13%) |
| LVDd (mm) | 49 ± 8 |
| LVEF (%) | 50.8 ± 13 |
| LVEF < 40 (%) | 19 (22%) |
| 40 ≦ LVEF < 60 (%) | 41 (48%) |
| LVEF ≧ 60 (%) | 26 (30%) |
| E/e′ | 12.5 ± 5 |
| E/e′ < 8 | 13 (15%) |
| 8 ≦ E/e′ ≦ 14 | 50 (58%) |
| E/e′ > 14 | 23 (27%) |
| MR ≧ 3°/4 | 0 (0%) |
| Pre exercise | |
| Heart rate (bpm) | 74 ± 15 |
| Systolic BP (mm Hg) | 132 ± 26 |
| Peak exercise | |
| Heart rate (bpm) | 117 ± 23 |
| Systolic BP (mm Hg) | 169 ± 30 |
| AT (ml/min/kg) | 10.6 ± 2 |
| Peak VO2 (ml/min/kg) | 15.0 ± 3 |
| Peak WR (watt) | 65.5 ± 21 |
| VE/VCO2 slope | 38.9 ± 7 |
| Peak RER | 1.2 ± 0.1 |
| Amount of exercise during CR at outpatient visit | |
| Session attendance (times/3 months) | 6.6 |
Abbreviations: Scr, serum creatinine concentration; eGFRcr, estimated glomerular filtration rate based on Scr; Scys, serum concentration of cystatin-C; eGFRcys, eGFR based on Scys; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; E/e′, the ratio of the mitral peak velocity during early filling (E) to the early diastolic mitral annular velocity (e′); AT, anaerobic threshold; Peak VO2, peak oxygen uptake; Peak WR, peak work rate; VE/VCO2 slope, The slope of the relationship between the ventilation (VE) and VCO2 up until the respiratory compensation point; Peak RER, ratio of the carbon dioxide output and oxygen uptake at peak exercise.
Fig. 2The change in the exercise capacity and renal function after CR.
Abbreviations: CKDcys, CKD as defined with the aid of the eGFRcys.
Fig. 3The change in the renal function of CKD G3b group after CR.
Abbreviations: CKDcys, CKD as defined with the aid of the eGFRcys.
Baseline characteristics of CKD subgroups.
| CKD G3a ( | CKD G3b ( | CKD G4 ( | |
|---|---|---|---|
| Age (years) | 73 ± 9 | 77 ± 7 | 77 ± 7 |
| Sex (M/F) | 35/16 | 16/8 | 10/1 |
| BMI (kg/m2) | 22.3 ± 3 | 22.8 ± 3 | 21.3 ± 2 |
| Angina pectoris | 18 (35%) | 10 (42%) | 3 (27%) |
| Myocardial infarction | 16 (31%) | 4 (17%) | 2 (18%) |
| Silent myocardial ischemia | 9 (18%) | 4 (17%) | 2 (18%) |
| Non-ischemic heart failure | 11 (22%) | 5 (21%) | 2 (18%) |
| Post-cardiac surgery | 16 (31%) | 8 (33%) | 6 (55%) |
| Smoking | 29 (57%) | 12 (50%) | 9 (82%) |
| Hypertension | 29 (57%) | 16 (67%) | 9 (82%) |
| Diabetes mellitus | 16 (31%) | 12 (50%) | 5 (45%) |
| Dyslipidemia | 29 (57%) | 16 (67%) | 7 (64%) |
| Family history | 11 (22%) | 4 (17%) | 1 (9%) |
| ACE-I/ARB | 24 (47%) | 15 (63%) | 5 (45%) |
| Βeta-blocker | 35 (69%) | 13 (54%) | 10 (91%) |
| Diuretics | 34 (67%) | 20 (83%) | 9 (82%) |
| Calcium channel blocker | 11 (22%) | 9 (38%) | 5 (45%) |
| Inotropic agents | 0 (0%) | 0 (0%) | 0 (0%) |
| Triglyceride (casual) (mg/dl) | 133 ± 57 | 133 ± 53 | 124 ± 50 |
| LDL-Chol (mg/dl) | 93 ± 33 | 98 ± 29 | 99 ± 32 |
| HDL-Chol (mg/dl) | 54 ± 16 | 46 ± 12 | 55 ± 14 |
| Blood glucose (casual) (mg/dl) | 128 ± 38 | 128 ± 41 | 148 ± 75 |
| HbA1c (%) | 6.2 ± 0.8 | 6.2 ± 0.6 | 6.0 ± 0.8 |
| BNP (pg/ml) | 215 ± 247 | 137 ± 119 | 455 ± 579 |
| Hb (g/dl) | 12.8 ± 1.6 | 12.1 ± 1.4 | 10.7 ± 1.7 |
| Scr (mg/dl) | 1.0 ± 0.2 | 1.2 ± 0.2 | 2.0 ± 0.3 |
| eGFRcr (ml/min/1.73 m2) | 50.9 ± 8.9 | 41.5 ± 8.4 | 25.8 ± 5.3 |
| Scys (mg/l) | 1.2 ± 0.1 | 1.6 ± 0.1 | 2.4 ± 0.3 |
| eGFRcys (ml/min/1.73 m2) | 53.3 ± 4.0 | 38.0 ± 3.9 | 23.3 ± 3.6 |
| CRP (mg/dl) | 0.19 ± 0.20 | 0.43 ± 0.66 | 0.67 ± 0.98 |
| LVDd (mm) | 51 ± 8 | 47 ± 6 | 49 ± 8 |
| LVEF (%) | 50 ± 13 | 54 ± 11 | 49 ± 14 |
| LVEF < 40 (%) | 13 (25%) | 2 (8%) | 4 (36%) |
| 40 ≦ LVEF < 60 (%) | 25 (49%) | 13 (54%) | 3 (27%) |
| LVEF ≧ 60 (%) | 13 (25%) | 9 (38%) | 4 (36%) |
| E/e′ | 11.8 ± 4 | 12.1 ± 4 | 16.4 ± 8 |
| E/e′ < 8 | 8 (16%) | 4 (17%) | 1 (9%) |
| 8 ≦ E/e′ ≦ 14 | 31 (61%) | 13 (54%) | 4 (36%) |
| E/e′ > 14 | 12 (24%) | 7 (29%) | 6 (55%) |
| MR ≧ 3°/4 | 0 (0%) | 0 (0%) | 0 (0%) |
| Pre exercise | |||
| Heart rate (bpm) | 75 ± 16 | 77 ± 12 | 66 ± 14 |
| Systolic BP (mm Hg) | 131 ± 29 | 127 ± 18 | 145 ± 20 |
| Peak exercise | |||
| Heart rate (bpm) | 122 ± 25 | 115 ± 17 | 103 ± 24 |
| Systolic BP (mm Hg) | 171 ± 31 | 166 ± 32 | 171 ± 17 |
| AT (ml/min/kg) | 10.7 ± 2 | 10.7 ± 2 | 9.8 ± 2 |
| Peak VO2 (ml/min/kg) | 15.7 ± 3 | 14.0 ± 3 | 13.9 ± 3 |
| Peak WR (watt) | 68.5 ± 23 | 61.6 ± 17 | 59.9 ± 17 |
| VE/VCO2 slope | 38.4 ± 7 | 38.7 ± 6 | 41.3 ± 5 |
| Peak RER | 1.17 ± 0.1 | 1.19 ± 0.1 | 1.22 ± 0.1 |
| Amount of exercise during CR at outpatient visit | |||
| Session attendance (times/3 months) | 6.2 | 7.5 | 6.5 |
CKD G3a vs CKD G4, CKD G3b vs CKD G4, p = 0.014.
CKD G3a vs CKD G4, CKD G3b vs CKD G4, p = 0.000.
CKD G3a vs CKD G3b vs CKD G4, p = 0.000.
CKD G3a vs CKD G4, p = 0.014.
CKD G3a vs CKD G4, CKD G3b vs CKD G4, p = 0.020.
CKD G3a vs CKD G3b, p = 0.036.